Table 2.
Important recent trials regarding regional nodal irradiation in breast cancer
| EORTC 22922/10925 |
MA.20 |
French Trial [45] |
DBCG-IMN [47] |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| WBI + boost TWI | WBI + boost + SCV/IMN TWI + SCV/IMN | p | WBI + boost | WBI + boost + SCV/IMN | p | TWI + SCV | TWI + SCV/IMN | p | WBI + boost + SCV (left-sided tumour) | WBI + boost + SCV/IMN (right-sided tumour) | p | |
| Patients, n | 4,004 | 1,832 | 1,334 | 3,089 | ||||||||
| Median follow-up, years | 10.9 | 9.5 | 8.6 | 8.9 | ||||||||
| Inclusion criteria | N+ or N0 (medial or central tumour location) | N+ or N0 high risk (T3 or T2 with <10 resected lymph nodes and additional risk factors present) | N+ or N0 (medial or central tumour location) | N+ | ||||||||
| Disease-free | 69.1 | 72.1 | 0.04 | 77.0 | 82.0 | 0.01 | 49.9 | 53.2 | 0.35 | not stated | - | |
| survival, % | ||||||||||||
| Overall survival, % | 80.7 | 82.3 | 0.06 | 81.8 | 82.8 | 0.38 | 59.3 | 62.6 | 0.8 | 72.2 | 75.9 | 0.005 |
WBI = Whole breast irradiation; TWI = thoracic wall irradiation; SCV = supra-/infraclavicular region; IMN = internal mammary lymph nodes.